The antioxidant properties of α-tocopherol have been proposed to play a beneficial chemopreventive role against cancer. However, emerging data also indicate that it may exert contrasting effects on the efficacy of chemotherapeutic treatments when given as dietary supplement, being in that case harmful for patients. This dual role of α-tocopherol and, in particular, its effects on the efficacy of anticancer drugs remains poorly documented. For this purpose, we studied here, using high throughput flow cytometry, the direct impact of α-tocopherol on apoptosis and cell cycle arrest induced by different cytotoxic agents on various models of cancer cell lines in vitro. Our results indicate that physiologically relevant concentrations of α-tocopherol strongly compromise the cytotoxic and cytostatic action of various protein kinase inhibitors (KI), while other classes of chemotherapeutic agents or apoptosis inducers are unaffected by this vitamin. Interestingly, these anti-chemotherapeutic effects of α-tocopherol appear to be unrelated to its antioxidant properties since a variety of other antioxidants were completely neutral toward KI-induced cell cycle arrest and cell death. In conclusion, our data suggest that dietary α-tocopherol could limit KI effects on tumour cells, and, by extent, that this could result in a reduction of the clinical efficacy of anti-cancer treatments based on KI molecules.
References
[1]
Evans HM, Bishop KS (1922) On the Existence of a Hitherto Unrecognized Dietary Factor Essential for Reproduction. Science 56: 650–651.
[2]
Ricciarelli R, Zingg JM, Azzi A (2001) Vitamin E: protective role of a Janus molecule. Faseb J 15: 2314–2325.
[3]
Sigounas G, Anagnostou A, Steiner M (1997) dl-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Nutr Cancer 28: 30–35.
[4]
Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA (1998) Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 4: 1189–1192.
[5]
Keaney JF Jr, Simon DI, Freedman JE (1999) Vitamin E and vascular homeostasis: implications for atherosclerosis. Faseb J 13: 965–975.
[6]
Azzi A, Stocker A (2000) Vitamin E: non-antioxidant roles. Prog Lipid Res 39: 231–255.
[7]
Bowry VW, Stanley KK, Stocker R (1992) High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A 89: 10316–10320.
[8]
Upston JM, Terentis AC, Stocker R (1999) Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. Faseb J 13: 977–994.
[9]
Boscoboinik D, Szewczyk A, Hensey C, Azzi A (1991) Inhibition of cell proliferation by alpha-tocopherol. Role of protein kinase C. J Biol Chem 266: 6188–6194.
[10]
Tasinato A, Boscoboinik D, Bartoli GM, Maroni P, Azzi A (1995) d-alpha-tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties. Proc Natl Acad Sci U S A 92: 12190–12194.
[11]
Freedman JE, Farhat JH, Loscalzo J, Keaney JF Jr (1996) alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 94: 2434–2440.
[12]
Devaraj S, Li D, Jialal I (1996) The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1 beta secretion, and monocyte adhesion to endothelium. J Clin Invest 98: 756–763.
[13]
Devaraj S, Adams-Huet B, Fuller CJ, Jialal I (1997) Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation. Arterioscler Thromb Vasc Biol 17: 2273–2279.
[14]
Tada H, Ishii H, Isogai S (1997) Protective effect of D-alpha-tocopherol on the function of human mesangial cells exposed to high glucose concentrations. Metabolism 46: 779–784.
[15]
Devaraj S, Jialal I (1999) Alpha-tocopherol decreases interleukin-1 beta release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler Thromb Vasc Biol 19: 1125–1133.
[16]
Martin-Nizard F, Boullier A, Fruchart JC, Duriez P (1998) Alpha-tocopherol but not beta-tocopherol inhibits thrombin-induced PKC activation and endothelin secretion in endothelial cells. J Cardiovasc Risk 5: 339–345.
[17]
Cachia O, Benna JE, Pedruzzi E, Descomps B, Gougerot-Pocidalo MA, et al. (1998) alpha-tocopherol inhibits the respiratory burst in human monocytes. Attenuation of p47(phox) membrane translocation and phosphorylation. J Biol Chem 273: 32801–32805.
[18]
Aratri E, Spycher SE, Breyer I, Azzi A (1999) Modulation of alpha-tropomyosin expression by alpha-tocopherol in rat vascular smooth muscle cells. FEBS Lett 447: 91–94.
[19]
Ricciarelli R, Zingg JM, Azzi A (2000) Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation 102: 82–87.
[20]
Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. Jama 297: 842–857.
[21]
Sylvester PW (2007) Vitamin E and apoptosis. Vitam Horm 76: 329–356.
[22]
Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S (2005) Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 76: 1439–1453.
[23]
Temkin V, Karin M (2007) From death receptor to reactive oxygen species and c-Jun N-terminal protein kinase: the receptor-interacting protein 1 odyssey. Immunol Rev 220: 8–21.
[24]
Sordet O, Khan QA, Plo I, Pourquier P, Urasaki Y, et al. (2004) Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals. J Biol Chem 279: 50499–50504.
[25]
Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789–802.
[26]
Baldwin EL, Osheroff N (2005) Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 5: 363–372.
[27]
Schembri L, Zanese M, Depierre-Plinet G, Petit M, Elkaoukabi-Chaibi A, et al. (2009) Recombinant differential anchorage probes that tower over the spatial dimension of intracellular signals for high content screening and analysis. Anal Chem 81: 9590–9598.
[28]
Gulcin I, Alici HA, Cesur M (2005) Determination of in vitro antioxidant and radical scavenging activities of propofol. Chem Pharm Bull (Tokyo) 53: 281–285.
[29]
Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, et al. (2001) Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19: 1485–1492.
[30]
Monnerat C, Henriksson R, Le Chevalier T, Novello S, Berthaud P, et al. (2004) Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 15: 316–323.
[31]
Vignot S, Soria JC, Spano JP, Mounier N (2008) [Protein kinases C: a new cytoplasmic target]. Bull Cancer 95: 683–689.
[32]
Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5: 172–183.
[33]
Druker BJ (2004) Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91: 1–30.
[34]
Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542–2551.
[35]
Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, et al. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129–141.
[36]
Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399–401.
[37]
Bean J, Brennan C, Shih JY, Riely G, Viale A, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104: 20932–20937.
[38]
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.
[39]
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500.
[40]
Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306–13311.
[41]
Stanner SA, Hughes J, Kelly CN, Buttriss J (2004) A review of the epidemiological evidence for the ‘antioxidant hypothesis’. Public Health Nutr 7: 407–422.
[42]
Berger MM (2005) Can oxidative damage be treated nutritionally? Clin Nutr 24: 172–183.
[43]
Bjelakovic G, Nikolova D, Simonetti RG, Gluud C (2004) Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 364: 1219–1228.
[44]
Ishizaki Y, Voyvodic JT, Burne JF, Raff MC (1993) Control of lens epithelial cell survival. J Cell Biol 121: 899–908.
[45]
Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S (1994) Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 54: 1707–1714.
[46]
Gescher A (1998) Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol 31: 721–728.
[47]
Ahlemeyer B, Krieglstein J (2000) Inhibition of glutathione depletion by retinoic acid and tocopherol protects cultured neurons from staurosporine-induced oxidative stress and apoptosis. Neurochem Int 36: 1–5.
[48]
Kruman I, Guo Q, Mattson MP (1998) Calcium and reactive oxygen species mediate staurosporine-induced mitochondrial dysfunction and apoptosis in PC12 cells. J Neurosci Res 51: 293–308.
[49]
Coyoy A, Valencia A, Guemez-Gamboa A, Moran J (2008) Role of NADPH oxidase in the apoptotic death of cultured cerebellar granule neurons. Free Radic Biol Med 45: 1056–1064.
[50]
Azzi A, Boscoboinik D, Chatelain E, Ozer NK, Stauble B (1993) d-alpha-tocopherol control of cell proliferation. Mol Aspects Med 14: 265–271.
[51]
Chatelain E, Boscoboinik DO, Bartoli GM, Kagan VE, Gey FK, et al. (1993) Inhibition of smooth muscle cell proliferation and protein kinase C activity by tocopherols and tocotrienols. Biochim Biophys Acta 1176: 83–89.
[52]
Yano M, Kishida E, Iwasaki M, Kojo S, Masuzawa Y (2000) Docosahexaenoic acid and vitamin E can reduce human monocytic U937 cell apoptosis induced by tumor necrosis factor. J Nutr 130: 1095–1101.
